促红细胞生成素和早产儿视网膜病变：2008-2018 年日本的回顾性队列研究。
Erythropoietin and retinopathy of prematurity: a retrospective cohort study in Japan, 2008-2018.
机构信息
Division of Neonatology, National Center for Child Health and Development, Tokyo, Japan.
Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
出版信息
J Perinatol. 2024 Jun;44(6):886-891. doi: 10.1038/s41372-024-01929-z. Epub 2024 Mar 21.
BACKGROUND
Erythropoietin has an angiogenic effect on the retina and might increase the risk of retinopathy of prematurity (ROP).
METHODS
This retrospective cohort study included infants born at 22 to 27 weeks' gestation between 2008 and 2018 who were admitted to neonatal intensive care units (NICUs). We compared mortality and morbidities between infants who received erythropoietin and those who did not.
RESULTS
Among 18,955 livebirth infants, this study included 16,031 infants, among which 14,373 infants received erythropoietin. The risk of ROP requiring treatment was significantly higher in the erythropoietin group than in the control group (33% vs. 26%; aOR 1.50 [95% CI 1.28-1.76]). On the other hand, the erythropoietin group had lower risks of death and necrotizing enterocolitis.
CONCLUSIONS
This study with a large sample size found that erythropoietin use was associated with increased risk of ROP requiring treatment, while being associated with reductions in deaths and NEC.
背景
促红细胞生成素对视网膜具有血管生成作用，可能会增加早产儿视网膜病变（ROP）的风险。
方法
本回顾性队列研究纳入了 2008 年至 2018 年间胎龄为 22 至 27 周、入住新生儿重症监护病房（NICU）的婴儿。我们比较了接受促红细胞生成素治疗和未接受治疗的婴儿的死亡率和并发症发生率。
结果
在 18955 例活产婴儿中，本研究纳入了 16031 例婴儿，其中 14373 例婴儿接受了促红细胞生成素治疗。接受促红细胞生成素治疗的婴儿发生需要治疗的 ROP 的风险明显高于对照组（33% vs. 26%；aOR 1.50 [95% CI 1.28-1.76]）。另一方面，促红细胞生成素组的死亡和坏死性小肠结肠炎的风险较低。
结论
这项具有较大样本量的研究发现，促红细胞生成素的使用与需要治疗的 ROP 风险增加相关，同时与死亡率和 NEC 的降低相关。
Zotero 插件